Fundraising Fox
/Companies
Sign in

Eclipseregenesis

Founded 2017 · 8 employees on LinkedIn · 1 known investors

Find your way into Eclipseregenesis

Sign up to see every warm intro you have to Eclipseregenesis

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Eclipseregenesis team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Eclipse Regenesis develops a regenerative therapy platform for treating intestinal failure, starting with Short Bowel Syndrome, and extending to other complex gastrointestinal conditions. The company is a medical device developer focused on enabling the body's own tissue to rebuild rather than relying on invasive replacements.

BiotechHealthtechMedical Devices

Founders & leadership

Eclipseregenesis was founded in 2017 by Andre Bessette, James Dunn, and Tom Krummel.

ABAndre Bessette
Andre BessetteCEO, Co-FounderAndre Bessette brings 28 years of medical device industry experience, including roles as an executive at companies acquired by ArthroCare and PEAK Surgical (acquired by Medtronic), where he managed product lines and led global commercialization teams. He is CEO and co-founder of Eclipse Regenesis, which develops regenerative therapy technologies for treating intestinal failure and other gastrointestinal conditions.
JDJames Dunn
James DunnCo-Founder
TKTom Krummel
Tom KrummelCo-Founder

Investors · 1

Non-dilutive funding · 4 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Science FoundationPhase II2023$970.5K
National Institutes of Health (NIH)National Institutes of HealthPhase II2022$1.4M
National Institutes of Health (NIH)National Institutes of HealthPhase I2021$423.2K
National Science FoundationPhase I2021$256K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Eclipseregenesis do?
Eclipse Regenesis develops a regenerative therapy platform for treating intestinal failure, starting with Short Bowel Syndrome, and extending to other complex gastrointestinal conditions. The company is a medical device developer focused on enabling the body's own tissue to rebuild rather than relying on invasive replacements.
Who founded Eclipseregenesis?
Eclipseregenesis was founded by Andre Bessette, James Dunn, Tom Krummel in 2017.
Who are Eclipseregenesis's investors?
Eclipseregenesis's investors include Atacama Ventures.